ENB Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ENB Therapeutics is an emerging oncology biotech advancing ENB-003, a small molecule designed to modulate the tumor microenvironment, potentially overcoming resistance to checkpoint inhibitors. Its strategy is validated by a clinical collaboration with Coherus BioSciences and the Cancer Research Institute to combine ENB-003 with toripalimab in ovarian cancer. The company is pre-revenue, privately held, and operates with a lean structure, leveraging partnerships to advance its pipeline. Its success hinges on demonstrating clinical proof-of-concept for its novel mechanism in a challenging indication.

Oncology

Technology Platform

Small molecule discovery platform focused on modulating the tumor immune microenvironment to overcome resistance to checkpoint inhibitor therapy.

Opportunities

A successful clinical proof-of-concept for ENB-003 could address the vast unmet need in checkpoint inhibitor-resistant ovarian cancer and establish a platform applicable to other 'cold' tumors.

The collaboration with Coherus and CRI provides validation, non-dilutive funding, and expert trial execution.

Risk Factors

High clinical risk that ENB-003 fails to demonstrate efficacy or has unacceptable toxicity.

Financial dependency on future fundraising rounds in a challenging capital environment.

Intense competition from numerous other approaches aiming to overcome immunotherapy resistance.

Competitive Landscape

ENB operates in the crowded immuno-oncology space, competing with dozens of biotechs and pharma companies developing combination therapies to modulate the tumor microenvironment. Competitors include firms targeting similar pathways (e.g., CCR2/5, CXCR2, IDO, adenosine) with small molecules, antibodies, and other modalities.

More companies in Small Molecule Drugs →More companies in United States →